Madrigal Pharmaceuticals reported strong first-quarter revenue growth driven by Rezdiffra adoption while expanding its MASH pipeline through new siRNA licensing and development agreements.
Key Investor Takeaways
- Madrigal Pharmaceuticals (NASDAQ:MDGL) reported first-quarter 2026 revenue growth of 127% as Rezdiffra achieved blockbuster status on a trailing 12-month basis.
- The company expanded its MASH pipeline with a newly licensed siRNA asset targeting the PNPLA3 mutation and six additional preclinical siRNA programs.
- Rezdiffra adoption continued to grow, supported by physician uptake and increasing patient demand in the MASH market.
- Operating expenses rose significantly due to pipeline expansion costs and continued commercial investment.
- Investors may focus on long-term market opportunity in MASH, pipeline diversification, and the company’s ability to manage spending while scaling commercialization.
Why MDGL Stock Is in Focus
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported first-quarter 2026 financial results highlighted by strong Rezdiffra sales growth and expansion of its MASH-focused pipeline.
Net revenue for the quarter reached $311.3 million, up 127% from $137.3 million during the same period last year.
The company said Rezdiffra achieved blockbuster status on a trailing 12-month net sales basis, driven by broad physician adoption and rising patient demand.
CEO Bill Sibold stated that the diagnosed MASH patient population has expanded nearly 50% over the last two years to approximately 460,000 patients.
“2026 is off to a terrific start,” Sibold said.
“Rezdiffra has achieved blockbuster status on a trailing-12-month net sales basis, reflecting broad physician adoption and high patient demand.”
Madrigal also announced a licensing agreement with Arrowhead Pharmaceuticals for global rights to ARO-PNPLA3, a clinical-stage siRNA candidate targeting a genetic mutation linked to advanced liver fibrosis in MASH patients.
According to the company, Phase 1 data for the asset showed up to a 46% reduction in liver fat after a single dose in certain genetically defined patients.
In addition, Madrigal disclosed that it expanded its pipeline earlier this year with six preclinical siRNA programs focused on next-generation MASH therapies.
The company plans to present eight abstracts at the upcoming EASL Congress, including data tied to cardiovascular risk markers and real-world Rezdiffra outcomes.
Higher Spending Reflects Commercial and Pipeline Expansion
Operating expenses increased to $404.1 million during the quarter, compared with $216.6 million in the prior-year period.
The increase included $54.3 million in one-time business development expenses tied to pipeline expansion activities.
Research and development expenses rose to $108.7 million, while SG&A expenses increased to $268.5 million due to expanded commercial investments, including endocrinology field force growth and direct-to-consumer marketing efforts.
Madrigal reported a quarterly net loss of $94.4 million, compared with a loss of $73.2 million a year earlier.
Cash, cash equivalents, restricted cash, and marketable securities totaled $817.9 million as of March 31, 2026.
Why This Matters for Investors
The update reinforces Madrigal’s position as an early commercial leader in the rapidly expanding MASH treatment market following Rezdiffra’s launch.
Strong revenue growth and physician adoption may support the company’s long-term commercialization narrative, especially given the limited number of approved therapies currently available for MASH patients with fibrosis.
The expansion into genetically targeted siRNA therapies also suggests Madrigal is attempting to build a broader franchise that could support combination treatment approaches across different patient populations.
At the same time, rising operating expenses and continued net losses may remain an area of investor focus as the company scales commercial operations and advances pipeline development.
The company’s long-term growth outlook may also depend on continued reimbursement expansion, physician adoption trends, competitive dynamics, and future clinical data.
What To Watch Next
Investors may monitor:
- Continued prescription and revenue growth for Rezdiffra
- Progress of ARO-PNPLA3 and other siRNA pipeline programs
- Data presentations at the upcoming EASL Congress
- Results from the ongoing Phase 3 trial in compensated MASH cirrhosis
- Commercial spending trends and cash utilization
- Expansion of the diagnosed MASH patient population